Title : Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.

Pub. Date : 2013 Jun

PMID : 23435872






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this scenario, regorafenib has emerged as a novel, orally active, multitarget compound with potent activity against a number of angiogenic and stromal TKs, including vascular endothelial growth factor receptor 2 (VEGFR-2), tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (TIE-2), fibroblast growth factor receptor 1 (FGFR-1), and platelet-derived growth factor receptor (PDGFR). regorafenib platelet derived growth factor receptor beta Homo sapiens
2 In this scenario, regorafenib has emerged as a novel, orally active, multitarget compound with potent activity against a number of angiogenic and stromal TKs, including vascular endothelial growth factor receptor 2 (VEGFR-2), tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (TIE-2), fibroblast growth factor receptor 1 (FGFR-1), and platelet-derived growth factor receptor (PDGFR). regorafenib platelet derived growth factor receptor beta Homo sapiens